IR@PKUHSC  > 北京大学深圳医院
学科主题临床医学
Development and Validation of a New HPV Genotyping Assay Based on Next-Generation Sequencing
Yi, Xin1,2; Zou, Jing1; Xu, Jiajia2; Liu, Tao2; Liu, Tengfei1; Hua, Sang1; Xi, Feng1; Nie, Xifang2; Ye, Lili1; Luo, Yufen1; Xu, Lin1; Du, Hui3; Wu, Ruifang3; Yang, Ling2; Liu, Ren4; Yang, Bin5; Wang, Jian1; Belinson, Jerome L.6
关键词Cervical cancer screening Self-sampling HPV genotyping test Next-generation sequencing (NGS) Ion Torrent PGM MiSeq
刊名AMERICAN JOURNAL OF CLINICAL PATHOLOGY
2014-06-01
DOI10.1309/AJCP9P2KJSXEKCJB
141期:6页:796-804
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Pathology
研究领域[WOS]Pathology
关键词[WOS]HIGH-RISK HPV ; HUMAN-PAPILLOMAVIRUS TYPES ; MASS-SPECTROMETRY SYSTEM ; CERVICAL-CANCER ; CLINICAL-TRIAL ; PERFORMANCE ; PLATFORMS ; LESIONS ; DETECT ; CHINA
英文摘要

Objectives: We developed a new human papillomavirus (HPV) genotyping assay based on multiplex polymerase chain reaction and next-generation sequencing (NGS) methods for large-scale cervical cancer screening.

Methods: We first trained the assay on 1,170 self-collected samples, balancing the cutoff points for high-risk types. Then using 4,262 separate self-collected specimens, we compared concordance, sensitivity, and specificity for cervical intraepithelial neoplasia type 2 (CIN2) or higher and CIN type 3 (CIN3) or higher of the HPV sequencing assay with that of Hybrid Capture 2 (HC2) direct samples and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay self-samples.

Results: All assays had a good agreement. The sensitivity for CIN2 or higher and CIN3 or higher of the self-sampling specimens tested with the sequencing assay run on both MiSeq and Ion Torrent Personal Genome Machine sequencer was similar to that of direct-sampling specimens tested with HC2 (P > .05), but the specificity of the sequencing assay for CIN2 or higher and CIN3 or higher was significantly higher than that of HC2 (P < .01).

Conclusions: This population-based study has demonstrated the applicability of a new NGS high-risk HPV assay for primary cervical cancer screening based on self-collection.

语种英语
WOS记录号WOS:000336239800007
资助机构Special Funds for Biotechnology Industry from Shenzhen Development and Reform Commission of China ; Funds for Shenzhen Clinical Molecular Diagnostic Engineering Laboratory from Shenzhen Development and Reform Commission of China ; Preventive Oncology International ; Hologic, Bedford, MA ; Qiagen, Gaithersburg, MD ; Gen-Probe, Bedford, MA ; Merck, Whitehouse Station, NJ ; GE Healthcare, Fairfield, CT
引用统计
被引频次:20[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/67952
专题北京大学深圳医院
作者单位1.BGI Shenzhen, Shenzhen, Peoples R China
2.BGI Tianjin, Tianjin, Peoples R China
3.Peking Univ, Shenzhen Hosp, Shenzhen, Peoples R China
4.Shenzhen Second Peoples Hosp, Shenzhen, Peoples R China
5.Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA
6.Cleveland Clin, Prevent Oncol Int & Womens Hlth Inst, Cleveland, OH 44106 USA
推荐引用方式
GB/T 7714
Yi, Xin,Zou, Jing,Xu, Jiajia,et al. Development and Validation of a New HPV Genotyping Assay Based on Next-Generation Sequencing[J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY,2014,141(6):796-804.
APA Yi, Xin.,Zou, Jing.,Xu, Jiajia.,Liu, Tao.,Liu, Tengfei.,...&Belinson, Jerome L..(2014).Development and Validation of a New HPV Genotyping Assay Based on Next-Generation Sequencing.AMERICAN JOURNAL OF CLINICAL PATHOLOGY,141(6),796-804.
MLA Yi, Xin,et al."Development and Validation of a New HPV Genotyping Assay Based on Next-Generation Sequencing".AMERICAN JOURNAL OF CLINICAL PATHOLOGY 141.6(2014):796-804.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yi, Xin]的文章
[Zou, Jing]的文章
[Xu, Jiajia]的文章
百度学术
百度学术中相似的文章
[Yi, Xin]的文章
[Zou, Jing]的文章
[Xu, Jiajia]的文章
必应学术
必应学术中相似的文章
[Yi, Xin]的文章
[Zou, Jing]的文章
[Xu, Jiajia]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。